ERBB2 and gastric cancer: IHC biomarkers (HER2 and MMR/MSI) were assessed in 33 (18.9%) of the 175 patients diagnosed with primary GC, EC, or GEJC (Tables 1 and 4), and these cases were considered adherent to clinical guidelines.